Objective. To determine the in vivo biocompatibility of septal neocartilage constructs developed in vitro by an alginate intermediate step.
N asal septal cartilage is widely used by head and neck reconstructive surgeons to repair cartilaginous defects of the nose. Its superior supportive properties, relative ease of harvest, and minimal donor site morbidity make it preferable over other autologous cartilage donor sources. The elastin content and innate curvilinear shape of auricular cartilage render it inferior for nasal defect repair. The acquisition of costal cartilage is associated with moderate to significant morbidity, and its use is associated with an unpredictable degree of absorption and warping. Septal cartilage is favored over synthetic and allogenic implants but is limited by the finite amount of available tissue and suboptimal geometric structure for reconstruction of larger craniofacial defects. [1] [2] [3] [4] Tissue engineering of autologous septal neocartilage therefore offers a potential alternative. Large quantities of autologous septal cartilage may be generated from a small specimen and then sculpted to the desired size and shape.
Cartilage tissue engineering studies, primarily using articular chondrocytes seeded onto scaffolds, have demonstrated improved histologic and mechanical properties after in vivo maturation. [5] [6] [7] Stiffness and failure load increased significantly when fibrinogen/polyglycolide-polylactide (PLGA)polymer bovine articular chondrocyte constructs were implanted into nude mice for 6 and 12 weeks. Formation of a chondron-like cell matrix with homogeneous distribution of chondrocytes was demonstrated upon staining with hematoxylin and eosin (H&E).
Few reports have focused on the in vivo implantation of tissue-engineered human septal cartilage. The development of tissue-engineered nasal septal constructs that possess the biomechanical and biological properties of native tissue has not yet been achieved. The aim of this study was to determine if in vivo implantation will foster maturation of human septal neocartilage constructs cultured in human serum (HS) and developed by the alginate-recovered chondrocyte (ARC) method. 8 Histologic, biochemical, and biomechanical properties of neocartilage constructs were evaluated.
Methods

Chondrocyte Isolation and Expansion
The study used remnant human septal specimens removed during routine surgery at the University of California, San Diego Medical Center or San Diego Veterans Affairs Medical Center (prior institutional review board approval). The cartilage specimens were dissected free of perichondrium and diced into pieces (1 mm 3 ). The fragments were digested as reported previously. 9 Suspensions of digested cartilage were filtered (70 mm) and then washed and centrifuged. Cells were resuspended in cell culture medium (Dulbecco's modified Eagle's medium [DMEM, low glucose], 2% pooled human AB serum [Gemini Bioproducts, Woodland, California], 25 mg/mL ascorbate, 0.4 mmol/L Lproline, 2 mmol/L L-glutamine, 0.1 mmol/L nonessential amino acids, 10 mmol/L HEPES buffer, 100 U/mL penicillin G, 100 mg/mL streptomycin sulfate, 0.25 mg/mL amphotericin B). The number of chondrocytes was determined by hemacytometer counting after Trypan blue exclusion.
For each patient, isolated chondrocytes were seeded at 5000 cells per cm 2 surface area into T-175 flasks. Monolayer cultures were incubated at 37°C with 5% carbon dioxide/air. Culture medium was supplemented with 1 ng/mL transforming growth factor beta-1 (TGFb-1), 5 ng/mL fibroblast growth factor-2 (FGF-2), and 10 ng/mL platelet-derived growth factor-bb (PDGF-bb) and changed every 2 days. Chondrocytes were grown until confluency (6-8 days) .
Culture in Alginate
The expanded cells were released from monolayer, resuspended in alginate, and cultured as described previously. 9 Alginate beads were depolymerized using a solution of 55 mM sodium citrate and 0.15 mM NaCl. Chondrocytes and cell-associated matrix (CAM) were recovered by centrifugation.
Formation of ARC Constructs
The recovered cells and CAM were resuspended in chondrocyte culture medium at a cell density of 4 3 10 6 cells/mL. This suspension was used to seed eight 12-mm diameter transwell polyester membrane inserts (Corning, Inc, Corning, New York) per donor at 2.5 3 10 6 cells/cm 2 . Culture medium was changed every other day for 5 weeks.
Transplantation of ARC Constructs into Nude Mice
A total of 8 athymic (nu/nu) mice were employed in the in vivo study according to a protocol approved by the university's Institutional Animal Care and Use Committee. Four mice were used for each donor (donors 1 and 2) constructs. After the mice were anesthetized using an intraperitoneal injection of 100 mg/kg ketamine and 10 mg/kg xylazine, a 2-cm incision was made along the midline of the dorsum of each mouse, and 2 separate subcutaneous pockets were made using blunt dissection. One ARC construct was placed in each of these pockets (same donor), and the incision was closed using 5-0 nylon sutures. Pre-and postimplant constructs were compared with native septal cartilage obtained from donors 3 and 4.
Termination of In Vivo Culture
Two mice were randomly chosen 30 days postsurgery to be sedated using 100 mg/kg ketamine and 10 mg/kg xylazine and euthanized by cervical dislocation. The other 2 mice were euthanized at 60 days postsurgery. An incision over the previous scar was made, and the constructs were removed using blunt dissection. Each construct was weighed upon its removal. A 9.6-mm diameter disk was punched from the center of each construct for biomechanical testing. The remainder of the construct was divided for structural and biochemical testing. The portions of sample used for biochemical testing were digested, one with proteinase K (PK) in phosphate-buffered EDTA and the other with pepsin, overnight. The remainder of the construct was used for live/dead assay of viability or placed in optimum cutting temperature (OCT) compound and frozen for histochemical analysis.
Live/Dead Assay
One slice, approximately 0.5 mm thick, was cut from the construct. The slice was stained using the LIVE/DEAD Viability/Cytotoxicity Kit (Molecular Probes, Eugene, Oregon). Calcein-AM and ethidium homodimer-1 dyes were prepared according to package instructions to 1003 concentration and then further diluted by combining 5 mL of each stain with 500 mL of phosphate-buffered saline (PBS). The construct slice was added to the dye solution at room temperature and protected from light. After 20 minutes, each slice was rinsed twice in 1 mL of PBS (10 minutes per rinse) and again protected from light. After staining, the construct was analyzed for cellular viability using fluorescence microscopy.
Histochemistry
Histological analysis was performed on the constructs to visualize the tissue morphology and to localize glycoaminoglycans (GAG). Samples to undergo histochemical analysis were placed in OCT compound and frozen by immersion in liquid nitrogen-cooled isopentane. They were sectioned in a cryostat at either 5 mm (implanted constructs) or 40 mm (preimplant constructs) thickness. For staining with H&E, slides from each sample group were stained sequentially in 0.6% (w/v) hematoxylin in a solution containing 0.06% (w/v) sodium iodate, 5.28% (w/v) aluminum sulfate hydrate, 25% (v/v) ethylene glycol, and 6% (v/v) glacial acetic acid in water (StatLab Medical Products, McKinney, Texas), then Scott's Bluing Reagent (StatLab Medical Products), followed by 0.025% (w/ v) Eosin Y in a solution containing 54% (v/v) denatured alcohol composed of 5 parts methanol, 3.6% (v/v) isopropanol, 1% (v/v) methyl isobutyl ketone, and 1% (v/v) glacial acetic acid in water (StatLab Medical Products), with rinses in water between each stain solution. The histochemical localization of GAG was performed as described in an earlier report. 10, 11 Quantitative Assay for DNA The DNA content was determined using portions of the PK digests and the PicoGreen DNA assay as described in a previous report. 9, 12 DNA content was normalized to determine cell number and also to milligrams of tissue wet weight.
Quantitative Assay for Glycosaminoglycans
The GAG content was determined, as reported previously, using portions of the PK digests and the dimethylmethylene blue (DMMB) reaction. 9 GAG content was normalized per milligram of tissue wet weight (before digestion) and to DNA content. 13 
Quantitative Assays for Type I and II Collagen
The amount of type I and type II collagen in PK digests was quantified by enzyme-linked immunosorbent assay (ELISA) using human type I and native type II collagen kits (Chrondrex, Inc, Redmond, Washington). Collagen was digested by sequential incubation with 5000 U/mL bovine hyaluronidase (Sigma-Aldrich, St Louis, Missouri) at 4°C overnight, followed by 2 incubations with 10 mg/ mL pepsin (Sigma-Aldrich) dissolved in 0.05 M acetic acid at 4°C overnight. Finally, the samples were incubated with 1 mg/mL pancreatic elastase (Sigma-Aldrich) at 4°C for 16 hours. Separate type I and type II collagen ELISAs were performed following the manufacturer's instructions. The optical density was read at 490 nm using a spectrophotometric plate reader. Collagen values were normalized per milligram of wet tissue weight (prior to digestion) and to DNA content.
Mechanical Testing
Following 2 months of in vivo implantation, a single construct was tested upon retrieval to assess material properties in tension. A tapered tensile specimen with a gauge region measuring 4 by 0.8 mm was punched through the construct center and then sliced into 3 layers, each~0.4 mm thick, using a vibrating microtome. The 3 layers spanned nearly the full thickness of the construct and comprised a top peripheral layer, including the graft surface previously contacting host tissue; a middle layer; and a bottom peripheral layer without the graft surface (outer 50 mm). Tensile tests were performed on a materials testing machine according to methods used previously to test native human septal cartilage. 14 Briefly, specimens were subjected to a tare load of 0.05 N and then elongated to 10% and 20% strain at 0.25%/ s with 900 seconds of relaxation to equilibrium at each strain step. Specimens were then pulled to failure at 5 mm/ min. An equilibrium tensile modulus was determined from the slope of a linear least squares fit of the data at 0%, 10%, and 20% strain steps. A dynamic tensile modulus was determined as the slope of a linear least squares fit of the data between 25% and 75% of the maximum stress during the pull to failure. Strength and failure strain were determined as the maximum stress and corresponding strain.
Statistical Analysis
Analysis was performed using Systat 10.2 (Systat Software, Chicago, Illinois). Means 6 SD are presented. Differences in proliferation, DNA, GAG, collagen, and confined compression modulus were assessed using a 1-way analysis of variance (ANOVA) to determine the fixed effect of time. If the ANOVA identified an overall significant effect, post hoc Tukey HSD (honestly significant difference) tests were used to identify significant differences between time points. A difference was considered significant when P .05.
Results
The athymic mice tolerated the neocartilage constructs well. Infection and extrusion were not observed during the course of the study. Upon recovery, each cartilage construct was surrounded by a thin fibrous capsule, separating the neocartilage from the murine tissue. The recovered cartilage constructs resembled normal cartilage with a smooth, firm, and opaque surface of solid, white tissue, which had maintained the original shape of the initial construct. The preimplant in vitro-cultured construct, however, was gelatinous and translucent ( Figure 1) . A live/dead viability assay performed after recovery of the implanted constructs revealed cell viability of greater than 90% (data not shown). Histologic examination of the recovered specimens showed neocartilage formation. Preimplant constructs were soft and fragile and were sectioned at a thickness of 40 mm. However, implanted constructs were more robust and were sectioned at a thickness of 5 mm. H&E staining of the implanted constructs showed homogeneous distribution of chondrocytes within a cell matrix, typical of native cartilage. 15 Alcian blue staining demonstrated robust staining, indicating the presence of sulfated GAG. The 60-day implants exhibited architecture more similar to native septal cartilage than the 30-day implants (Figure 2) .
Biochemical testing demonstrated a significant increase in construct DNA content, a surrogate measure of cell number, from preimplantation to both 30 and 60 days of in vivo culture, as well as between 30-and 60-day specimens (P \ .01; data not shown). GAG accumulation per construct wet weight decreased significantly after in vivo culture at 30 days and also between 30 and 60 days (P = .015 and P \ .0001, respectively; Figure 3 ). Preimplant construct GAG content was 10.74 6 0.42 mg per milligram wet weight, whereas the GAG content in 30-day and 60-day in vivo constructs was 8.86 6 0.38 and 2.73 6 1.16 mg per milligram wet weight, respectively. Type II collagen content increased significantly in preimplant constructs (0.02 6 0.003 mg per milligram wet weight) to 30-day in vivo constructs (0.78 6 0.12 mg per milligram wet weight; P = .004). In addition, a significant increase in type II collagen content was seen between 30-day and 60-day explants (0.78 6 0.12 and 1.44 6 0.006 mg per milligram wet weight, respectively; P = .005; Figure 4 ). Type Extractable type II collagen content increased significantly from preimplantation to 30 days of in vivo culture (P \.01). Type II collagen further increased from 30 days to 60 days of in vivo culture (P \.01). Error bars depict standard deviation.
I collagen content was below the limit of detection for the assay (0.08 mg/mL) for the preimplant constructs (data not shown). The type I collagen accumulation decreased from 30day explants to 60-day explants (0.54 6 0.14 and 0.40 6 0.10 mg per milligram wet weight, respectively; P = .003; data not shown). The ratio of type II collagen to GAG content in the preimplantation constructs was 0.002. This increased to 0.09 after 30 days of in vivo culture and 0.53 after 60 days of in vivo culture.
The biomechanical testing results were consistent with the biochemical content of the constructs. Only the 60-day explanted constructs possessed sufficient strength to complete accurate tensile testing. The dynamic modulus and failure strain of the 60-day explanted constructs were 4.93 6 1.49 MPa and 0.34 6 0.01 mm/mm, respectively. These results are similar to those of native septal cartilage, as can be seen in Table 1 .
Discussion
In this study, we demonstrated successful in vivo implantation and maturation of human septal neocartilage constructs. After both 30 and 60 days of implantation, the macroscopic examination and histological staining revealed the hyalinelike nature of the cartilage specimens. Neocartilage showed typical features of native cartilage. 15 Cells in the neocartilage appeared round in shape and homogeneously distributed within a cartilage matrix as seen in native cartilage. In addition, Alcian blue staining of the retrieved constructs after implantation showed a substantial accumulation of GAG. Development and maturation of the neocartilage was also marked by the increasing DNA content, as well as by decreasing levels of GAG and type I collagen with a concurrent increase in type II collagen content.
Maturation of the neocartilage was reflected in the significant gain in mechanical stability between the 30-and 60day groups. The dynamic modulus and failure strain of the 60-day implanted cartilage were similar to that of native human nasal septal cartilage, whereas the equilibrium modulus of the 60-day construct was approximately one-third that of native septal cartilage. These measures are influenced by different components of the tissue; the equilibrium modulus may be considered a more direct measure of the collagen network integrity, whereas the dynamic modulus is influenced by GAG and the interactions of collagen and GAG. This may suggest that although the biomechanical and biochemical properties of the construct are maturing, they do not yet fully resemble those of native cartilage. 16 It has been demonstrated that the growth of articular cartilage in vivo involves a greater net deposition of collagen than proteoglycan with a concomitant increase in mechanical integrity. In contrast, growth of explanted articular cartilage in vitro is associated with a greater net deposition of proteoglycan than collagen with inferior mechanical properties. 17 On the basis of this, we hypothesize that the ratio of type II collagen to GAG may serve as a better indicator of tissue maturity and development than either measure alone. The type II collagen to GAG ratio of native human septal cartilage is 3.03, with a range of 2.82 in young adults to 4.03 in patients older than 61 years. 11 A previous study by Alexander et al 9 determined a type II collagen to GAG ratio of 0.03 for human nasal septal chondrocyte constructs matured in vitro for 4 weeks. Preimplantation constructs in this study possessed a type II collagen to GAG content ratio of 0.002, which increased to 0.09 in 30-day explants and 0.53 in 60-day explants. It is evident that with in vivo maturation, the ratio of type II collagen to GAG content increased toward levels observed in native tissue.
Our results are consistent with those from other studies in which neocartilage constructs have been implanted into nude mice. Rotter et al 18 engineered human septal neocartilage using cells of individual patients cultured in autologous medium and from chondrocyte pools cultured in fetal bovine serum and seeded onto an Ethisorb-polymer. Following implantation into nude mice, the constructs formed from chondrocyte pools showed homogeneous distribution of extracellular matrix (ECM) components. Haisch et al 19 implanted PGLA-polymer human septal cartilage constructs in nude mice for 6 and 12 weeks and observed synthesis of abundant GAG matrix histologically. They also found that failure load and compressive modulus were not detectably different in 6-and 12-week constructs and native septal cartilage. The superior compressive modulus observed in this study when compared with results from our 60-day implant may be due to the addition of the polymer. Moreover, work by Farhadi et al 20 showed that human septal constructs precultured for 2 and 4 weeks demonstrated increased suture retention strength at the time of implantation and improved tensile and bending stiffness after explantation when compared with freshly seeded chondrocytes. Human septal chondrocytes embedded in an alginate polymer have also been injected into nude mice. Development of cartilage with this approach, however, is limited by the large pieces of cartilage required to isolate enough cells to achieve a desired density for injection. 21 By recovering the chondrocytes and developing neocartilage in vitro, we are able to generate a large number of chondrocytes with small amounts of cartilage.
Although the results of this study are encouraging, additional work is needed to produce optimal neocartilage constructs for clinical application. A large animal study is in progress to assess the effect of the defect created during harvesting of the initial piece of native cartilage. In addition, in vivo maturation will also be evaluated in the large animal model. In the current study, the neocartilage constructs are 12-mm-diameter cylinders. Cartilaginous defects of the nose range in size and shape. Further studies will be initiated to produce larger constructs with varying shapes to repair larger defects.
In this study, we show the feasibility of implanting septal neocartilage constructs in athymic mice. The neocartilage constructs exhibit an increase in DNA and type II collagen content with a concomitant decrease in GAG content, which is also reflected in the biomechanical properties. The constructs are biocompatible and show potential for in vivo maturation and eventual clinical application.
Author Contributions
Angela A. Chang, conception, design, conduct of research with collection and assembly of data, data interpretation, manuscript writing; Marsha S. Reuther, data analysis and interpretation, manuscript writing; Kristen K. Briggs, collection of data, data interpretation, manuscript writing; Barbara L. Schumacher, conception, design, collection of data, data interpretation; Gregory M. Williams, conception, design, collection of data, data interpretation; Maripat Corr, conception, design, collection of data; Robert L. Sah, conception, design, data interpretation; Deborah Watson, conception, design, provision of patients, data interpretation, manuscript writing and final approval.
Disclosures
